title: Activity of doramectin against nematode and arthropod parasites of swine.
abstract: The efficacy of doramectin, a novel avermectin, was assessed against both naturally-acquired and experimentally-induced infections of gastrointestinal roundworms, lungworms, kidneyworms, lice and mites in studies conducted across North America and Europe. Twenty-two studies evaluated efficacy against fourth larval and adult stages of the following nematode species: Hyostrongylus rubidus, Ascaris suum, Strongyloides ransomi, Oesophagostomum dentatum, Oesophagostomum quadrispinulatum, Trichuris suis, Metastrongylus spp. and Stephanurus dentatus. Efficacy was evaluated against the louse Haematopinus suis in six studies and against the mite Sarcoptes scabiei in four studies. A common study design was employed for each study type. In all studies, animals were allotted at random to a doramectin-treated or a saline-treated group. The doramectin-treated group received the drug at 300 micrograms kg-1 by intramuscular injection while the saline-treated group received saline by the same route. In the nematode studies, worm burdens were determined for each animal at slaughter 14-16 days after treatment. Efficacy against each nematode species/stage was assessed on the basis of percentage reduction in geometric mean worm burden in doramectin-treated animals compared with saline-treated controls. In louse and mite studies, counts were made immediately before treatment and then at weekly intervals for four weeks. Efficacy was based on a comparison of the level of infestation on the day of treatment with that on the last day of test. Data from individual studies were combined to derive a single estimate of efficacy against each of the parasite species represented in the study program. Efficacy of doramectin was 98% or greater against all nematode species except T. suis for which the efficacy was 87% and 79% against adult and fourth larval stage, respectively. Efficacy was 100% against both Haematopinus suis and Sarcoptes scabiei.
authors.affiliation: Pfizer Central Research, Groton, CT, USA.
authors.forename: N B
authors.initials: NB
authors.lastname: Logan
authors.forename: A J
authors.initials: AJ
authors.lastname: Weatherley
authors.forename: R M
authors.initials: RM
authors.lastname: Jones
mesh_terms: D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004424:Ear Canal / Q000469:parasitology; D005243:Feces / Q000469:parasitology; D007273:Injections, Intramuscular / Q000662:veterinary; D007306:Insecticides / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007411:Intestinal Diseases, Parasitic / Q000188:drug therapy / Q000469:parasitology / Q000662:veterinary; D007559:Ivermectin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D010373:Lice Infestations / Q000188:drug therapy / Q000469:parasitology / Q000662:veterinary*; D008174:Lung Diseases, Parasitic / Q000188:drug therapy / Q000469:parasitology / Q000662:veterinary; D009348:Nematoda / Q000187:drug effects; D009349:Nematode Infections / Q000188:drug therapy / Q000469:parasitology / Q000662:veterinary*; D008003:Phthiraptera; D011897:Random Allocation; D012520:Sarcoptes scabiei; D012532:Scabies / Q000188:drug therapy / Q000469:parasitology / Q000662:veterinary*; D012867:Skin / Q000469:parasitology; D013552:Swine; D013553:Swine Diseases / Q000188:drug therapy* / Q000469:parasitology; D014556:Urine / Q000469:parasitology
chemical_list: D000871:Anthelmintics; D007306:Insecticides; D007559:Ivermectin; C084101:doramectin